Press Releases

<< Back
May 7, 2018 at 8:30 AM EDT
Alder BioPharmaceuticals® to Present at the 2018 Bank of America Merrill Lynch Health Care Conference

BOTHELL, Wash., May 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. Cleveland, Interim President and Chief Executive Officer, at the 2018 Bank of America Merrill Lynch Health Care Conference at 1:15 p.m. PT on Tuesday, May 15, 2018 in Las Vegas, NV.

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit

Investor Relations Contacts:
Ashwin Agarwal
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.

Michael Schaffzin
Stern Investor Relations, Inc.

Media Contact:
Andy Brimmer / Aura Reinhard / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher

Primary Logo

Source: Alder BioPharmaceuticals, Inc.